Are you Dr. Petrich?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 56 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
676 N Saint Clair St
Ste 2100
Chicago, IL 60611Phone+1 312-695-6180Fax+1 312-695-4770
Summary
- Dr. Adam Petrich, MD is an oncologist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois. He is affiliated with Northwestern Memorial Hospital and is an Assistant Professor in Medicine-Hematology/Oncology at Northwestern University Medical School.
Education & Training
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2008 - 2011
- University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2005 - 2008
- University of Illinois College of MedicineClass of 2005
Certifications & Licensure
- IL State Medical License 2011 - 2017
Clinical Trials
- Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2010 Apr 15
- Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
- Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Start of enrollment: 2015 Jun 11
- Join now to see all
Publications & Presentations
PubMed
- A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter
Blood Advances. 2024-04-09 - 11 citationsEftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.Patricia LoRusso, Mark J Ratain, Toshihiko Doi, Drew W Rasco, Maja J A de Jonge
Investigational New Drugs. 2022-08-01 - 14 citationsA phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.William Pearse, Adam M. Petrich, Leo I. Gordon, Reem Karmali, Jane N. Winter
Leukemia & Lymphoma. 2021-08-02